Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 17/20 | 0.53 |
| ▸ | MAOA | P21397 | 16/20 | 0.53 |
| ▸ | MAOB | P27338 | 16/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13556691 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL15766923 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL3530324 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL15541000 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL23278434 | 0.86 | KDM1A (0.52) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL15541944 | 0.85 | KDM1A (0.55) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL15542258 | 0.85 | KDM1A (0.55) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL6623618 | 0.85 | KDM1A (0.55) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL16455153 | 0.83 | KDM1A (0.44) | KDM1AMAOAMAOB | |
| SCHEMBL17984248 | 0.83 | KDM1A (0.44) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | KDM1A 512/4885MAOA 1561/4885MAOB 1701/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | KDM1A 1248/4885MAOA 605/4885MAOB 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.